Rochester, Minn.-based Mayo Clinic has developed an artificial intelligence algorithm to identify patients with atrial fibrillation more likely to benefit from left atrial appendage occlusion than direct oral anticoagulants.
Researchers analyzed 744,190 adult patients treated between March 13, 2015, and Dec. 31, 2019. Forty percent were female, and the mean age was 76.8 years.
Thirty percent of patients were likely to benefit from left atrial appendage occlusion, 69.7% had a neutral response and 1.4% were potentially harmed. Older patients with higher comorbidity burdens were more likely to see benefits, according to an Aug. 16 news release.
Worldwide, 33.5 million people have atrial fibrillation, which carries a fivefold higher stroke risk. Direct oral anticoagulants are standard therapy but increase bleeding risk and pose adherence challenges. Left atrial appendage occlusion offers an alternative, though referral criteria remain uncertain, according to the release.
Researchers plan to validate the tool in prospective studies and refine the model with additional data to support clinical decision-making nationwide.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
